Pilot Trial: The effects of intravenous heme arginate on HO-1 expression and oxidative stress in the human heart - HO-1 in the Heart

Medizinische Universität Wien0 个研究点目标入组 31 人开始时间: 2013年4月19日最近更新: 2020年7月20日

试验速览

暂无简介。

•-Signed informed consent
•-Men and women aged between 40 and 85 years (inclusive)
•-Body mass index <35 kg/m2
•-Ability to communicate well with the investigator in the local language and to understand and comply with the requirements of the study
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 36
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 36

•-Known hypersensitivity to the study drug or any excipients of the drug formulation
•-Treatment with another investigational drug within 3 weeks prior to screening
•-History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study drug
•-Severe renal failure (glomerula filtration rate < 30ml/min)
•-Moderately or severe impaired left ventricular function (ejection fraction < 40%)
•-Moderately or severe impaired right ventricular function
•-Systolic pulmonary pressure > 45mmHg
•-Acute or recent (<7 days) myocardial infarction

发起方